JPRN-UMIN000011279
Completed
N/A
Independent study: Researching drug-drug interaction bitween etizolam and itraconazole - Independent clinical study (University of Tokyo)
P-One Clinic, Keikokai Medical Corp0 sites16 target enrollmentJuly 26, 2013
Conditionseurosis, somnipathy
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- eurosis, somnipathy
- Sponsor
- P-One Clinic, Keikokai Medical Corp
- Enrollment
- 16
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •a) Has hypotension (blood pressure of less than 100 mmHg during systole), hypertension (blood pressure of 140 mmHg or higher during systole) or diabetes (HbA1c NGSP 6\.5% or higher). b) Has donated or lost over 200 ml (1 unit) of blood within four weeks prior to study drug administration or 400 ml (2 units) within 3 months, or is anemic (less than Hb 12 g/dl). c) Has a serious neurological, cerebrovascular, hepatic, renal, endocrine, cardiovascular, digestive tract (including digestive tract disorders thought to impact trial drug absorption), respiratory, or metabolic disease in their medical history or as a concomitant condition. d) A clinically serious abnormality has been found by the principal investigator or one of the subinvestigators in the clinical test values, ECG or physical examination. e) Had a clinically serious illness within 30 days prior to study drug administration. f) Has used some sort of health food, grapefruit (including food containing it), or medical product within seven days prior to study drug administration or will use it during the study period. g) Has smoked tobacco or ingested nicotine within 30 days prior to study drug administration and, moreover, cannot abide by the prohibition on smoking during the study period. h) Cannot abide by the ban on caffeine and alcohol during the study period. i) Tested positive for a specific abused substance in the urine drug test at the screening. j) Tested positive for either HIV antibodies/antigens, HCV antibodies, or HBs antigens. 15\) Anything else that the principal investigator or one of the subinvestigators considers to be disqualifying.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Independent clinical study: Researching drug-drug interaction between aliskiren and sitagliptiHypertensionJPRN-UMIN000011598The University of Tokyo Hospital Unit for Early and Exploratory Clinical Development12
Completed
N/A
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancerprostate cancer10036958NL-OMON44408Johnson & Johnson Pharmaceutical10
Completed
N/A
Drug-drug interaction study to explore importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatihealthy male subjectsJPRN-UMIN000002477Clinical trial Center,Kitsato University East Hospital8
Completed
N/A
A Randomized, Drug-Drug Interaction Study to Assess the Safety and Pharmacokinetics of VNRX7145 and Ceftibuten (VNRX5024) in Healthy Adult VolunteersSerious infections10004018NL-OMON51149Venatorx Pharmaceuticals, Inc.54
Not Yet Recruiting
N/A
A SEARCH TO IDENTIFY ANY DRUG-DRUG INTERACTION AMONG PSYCHIATRY INPATIENTS IN A TERTIARY HEALTHCARE CENTREHealth Condition 1: F068- Other specified mental disorders due to known physiological conditionCTRI/2022/11/047051il